Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.

ABSTRACT:

Aim

To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs).

Methods

Ninety-six patients treated with DAAs, either alone (91) or in combination with PEG interferon (5), were tested for HCV-RNA and for HCV-Ag at baseline and at weeks 2, 4, 8 and 12 during treatment and 12 weeks after completion. The concordance and correlation between the viral parameters as well as the respective kinetics during and after treatment were evaluated.

Results

A sustained viral response (SVR) was achieved in 82 patients (91%), whereas 11 relapsed (R) and 1 showed a virological breakthrough while receiving treatment. HCV-RNA and

SUBMITTER: Loggi E 

PROVIDER: S-EPMC5681287 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature